From: MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients
MEN1 manifestations | Total | Mutation-positive | Mutation-negative |
---|---|---|---|
n (%) | n (%) | n (%) | |
Number of patients | 322 | 292 | 30 |
Primary hyperparathyroidism | 280 (87.0) | 252 (86.0) | 28 (93.3) |
Duodenopancreatic neuroendocrine tumors | 180 (55.9) | 173 (59.2) | 7 (23.3) |
Pituitary tumor | 141 (49.6) | 116 (39.7) | 25 (83.3) |
Lung neuroendocrine tumor | 62 (19.3) | 62 (21.2) | 0 |
Thymic neuroendocrine tumor | 13 (4.0) | 13 (4.5) | 0 |
Gastric neuroendocrine tumor | 12 (3.7) | 12 (4.1) | 0 |
Adrenal tumor | 101 (31.4) | 100 (34.1) | 1 (3.3) |